Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

Wednesday, September 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health, a precision oncology company, will present 20 abstracts at the 2026 World Conference on Lung Cancer. These presentations will focus on advancements in methylation-based tumor classification and liquid biopsy technology for lung cancer subtypes. The conference is organized by the International Association for the Study of Lung Cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Showcases advances in liquid biopsy technology.
  • Highlights collaboration with research partners.
  • Focus on early detection and treatment management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~54 mo
Minimal dilution risk
Lead asset
NSAI+ CDK4/6i
Phase 3 · HR Positive/HER-2 Negative Breast Cancer

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (WCLC). The conference is hosted by the International Association for the Study of Lung Cancer (IAS

Frequently Asked Questions

What will Guardant Health present at WCLC 2026?

Guardant Health will present 20 abstracts on liquid biopsy tests and tumor classification.

Who hosts the World Conference on Lung Cancer?

The conference is hosted by the International Association for the Study of Lung Cancer.

What is the focus of the presentations?

The presentations will focus on early detection and treatment management in lung cancer.

What type of technology is highlighted?

The technology highlighted includes methylation-based tumor classification and liquid biopsy.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health liquid biopsy lung cancer WCLC 2026 methylation-based tumor classification
Last updated: Sep 9, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~54 mo
Minimal dilution risk
Lead asset
NSAI+ CDK4/6iPhase 3
HR Positive/HER-2 Negative Breast Cancer →